Adaptation of Cognitive Enhancement Therapy for persons at Psychosis High Risk

 描述（由申请人提供）：处于精神病临床高危状态的人的特征是减弱或短暂的精神病发作、特质脆弱性和功能障碍。 赤字如果不治疗，很大比例的精神分裂症患者会出现不良后果，包括转化为精神病、其他精神病理学和功能退化。尽管在过去十年中加强了对艾滋病毒/艾滋病的研究，但几乎没有既定的预防方法。该提案旨在开发，评估可行性，可接受性，并获得关于认知增强的新手动方法的有效性的初步数据，在精神病临床高风险（CLUES）个体中进行学习和理解日常社会情境（CLUES）。这种方法是基于认知增强疗法（CET）的原则和方法，该研究小组表明，具有疗效，对功能结果的普遍性，持久性和可能的神经保护作用。 在第1阶段（0 - 6个月），我们将调整CET技术，以适应症状，功能和发展的特点，神经系统疾病，培训工作人员和开发评估程序和手册的CLUES干预的帮助下，焦点小组和输入从一个咨询小组的专家。在第2阶段，使用可行性试验（n = 8），我们将评估可接受性、耐受性、治疗依从性、治疗保真度，并获得目标参与的初步证据（即认知和社会认知的变化）。在第3阶段（19 - 36个月），我们将进行随机对照试验，以产生CLUES在40名个体（n = 30）中的初步功效、功能结果的概括、耐久性和耐受性数据。这些数据将作为一个先决条件，为以后，更大规模的干预研究的CLUES的人口。

 DESCRIPTION (provided by applicant): Persons at clinical high risk (CHR) state for psychosis are characterized by attenuated or transient psychotic episodes, trait vulnerability and functional deficits. If untreated, a significant proportion of CHR individuals have adverse outcomes, including conversion to psychosis, other psychopathology and functional deterioration. Despite enhanced CHR research focus over the past decade there are few established prevention approaches. This proposal seeks to develop, evaluate feasibility, acceptability and obtain preliminary data on efficacy of a novel manualized approach for cognitive enhancement, the Cognition for Learning and for Understanding Everyday Social Situations (CLUES) in individuals at clinical high risk (CHR) for psychosis. This approach is based on the principles and approaches of cognitive enhancement therapy (CET), shown by this research group to have efficacy, generalizability to functional outcome, durability and possible neuroprotective effects. In Phase 1 (0-6 months) we will adapt CET techniques to the symptomatic, functional, and developmental features of CHR, train staff and develop assessment procedures and a manual for the CLUES intervention with the help of a focus group and input from an advisory group of experts. In phase 2, using a feasibility trial (n=8) we will assess acceptability, tolerability, treatment adherence, treatment fidelity, and obtain preliminary evidence of target engagement (i.e. change in cognition and social cognition). .In Phase 3 (19-36 months) we will conduct a randomized control trial to generate pilot efficacy, generalization to functional outcome, durability and tolerability data on CLUES in CHR individuals (n=30). These data will serve as a prerequisite to a later, larger-scale intervention study of CLUES in the CHR population.